Omnicell completes Ateb acquisition
MOUNTAIN VIEW, Calif. — Omnicell on Wednesday announced that it had completed its acquisition of Ateb and its Canadian affiliate Ateb Canada. The company said the $41 million acquisition reinforces its commitment to improving patient care and outcomes by simplifying management of chronic conditions through increases access to adherence solutions.
With the acquisition, Omnicell adds to its portfolio Ateb’s Time My Meds, an integrated medication synchronization program that uses the appointment-based model of medication refill pickup and consultation in an effort to improve adherence and health outcomes. It adds to Omnicell’s existing offerings, which include its SureMed medication adherence packaging and related automation.
"By understanding the clinical and fiscal challenges these providers face, Omnicell now offers a portfolio of products and services that address the need for improved adherence across the continuum of care," Omnicell VP and GM medication adherence Troy Hilsenroth said. "We are excited about the strong potential of the combined entity, and to continue our mission of improving adherence and patient outcomes."